HBPCF (Helix BioPharma) Total Assets : $1.09 Mil (As of Jul. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma Total Assets?

Helix BioPharma's Total Assets for the quarter that ended in Jul. 2024 was $1.09 Mil.

During the past 12 months, Helix BioPharma's average Total Assets Growth Rate was 84.60% per year. During the past 3 years, the average Total Assets Growth Rate was -6.60% per year. During the past 5 years, the average Total Assets Growth Rate was -16.50% per year. During the past 10 years, the average Total Assets Growth Rate was -11.60% per year.

During the past 13 years, Helix BioPharma's highest 3-Year average Total Assets Growth Rate was 26.90%. The lowest was -45.30%. And the median was -13.80%.

Total Assets is connected with ROA %. Helix BioPharma's annualized ROA % for the quarter that ended in Jul. 2024 was -1,601.25%. Total Assets is also linked to Revenue through Asset Turnover. Helix BioPharma's Asset Turnover for the quarter that ended in Jul. 2024 was 0.00.

Helix BioPharma Total Assets Historical Data

The historical data trend for Helix BioPharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Total Assets Chart

Helix BioPharma Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Total Assets

Get a 7-Day Free Trial

3.64

3.24

2.88

0.78

1.09

Helix BioPharma Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Total Assets	Get a 7-Day Free Trial															0.78	1.38	0.26	0.84	1.09

Helix BioPharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Helix BioPharma's Total Assets for the fiscal year that ended in Jul. 2024 is calculated as

Total Assets	=	Total Equity (A: Jul. 2024 )	+	Total Liabilities (A: Jul. 2024 )
	=	-0.066	+	1.151
	=	1.09

Helix BioPharma's Total Assets for the quarter that ended in Jul. 2024 is calculated as

Total Assets	=	Total Equity (Q: Jul. 2024 )	+	Total Liabilities (Q: Jul. 2024 )
	=	-0.066	+	1.151
	=	1.09

Helix BioPharma (OTCPK:HBPCF) Total Assets Explanation

Total Assets is connected with ROA %.

Helix BioPharma's annualized ROA % for the quarter that ended in Jul. 2024 is

ROA %	=	Net Income (Q: Jul. 2024 )	/	( (Total Assets (Q: Apr. 2024 )	+	Total Assets (Q: Jul. 2024 ))	/ count )
	=	-15.396	/	( (0.837	+	1.086)	/ 2 )
	=	-15.396	/	0.9615
	=	-1,601.25 %

Note: The Net Income data used here is four times the quarterly (Jul. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Helix BioPharma's Asset Turnover for the quarter that ended in Jul. 2024 is

	Asset Turnover
=	Revenue (Q: Jul. 2024 )	/	( (Total Assets (Q: Apr. 2024 )	+	Total Assets (Q: Jul. 2024 ))	/ count )
=	0	/	( (0.837	+	1.086)	/ 2 )
=	0	/	0.9615
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Helix BioPharma Total Assets Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

HBP0:Germany HBP:Canada

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.